Q-omics provides the consensus-scored RPS6P3 profile across patient tissues and cancer cell-line models. RPS6P3 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPS6P3 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, RPS6P3 RNA expression shows 5,423 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, LUAD, and STAD as cancer lineages where RPS6P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS6P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS6P3 survival associations across molecular data types. RPS6P3 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS6P3 RNA expression–survival associations across cancer types. High RPS6P3 expression shows unfavorable associations in KIRP, ACC, DLBC and KICH, but favorable associations in LUSC and READ. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPS6P3 RNA expression.
This table summarizes RPS6P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS6P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS6P3 shows lower tumor expression in BRCA and STAD and higher tumor expression in LUAD. The LUAD box plot shows higher RPS6P3 RNA expression in tumor versus normal tissue (log2 FC = +0.031, t-test p = .022).
This table shows molecular features associated with RPS6P3 in patient tissues and cancer cell lines. In patient samples, RPS6P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
